Fig. 1.

Survey of benefits of subcutaneous immunoglobulin (SCIG) for patients. Percentage of US immunologists believing that patients would ultimately be better served by SCIG compared to intravenous immunoglobulin (IVIG). Physician members of the American Academy of Allergy Asthma and Immunology (AAAAI) were asked their opinion regarding IVIG and SCIG benefit in a web-based survey conducted in 2005–06. Importantly, this effort started before the US Food and Drug Administration (FDA) approved the use of SCIG in primary immunodeficiencies (PI) in the United States. Data adapted from Yong et al. 2010.